Literature DB >> 23299083

Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology.

Abdelbary Elhissi1, Kanar Hidayat, David A Phoenix, Enosh Mwesigwa, Stjohn Crean, Waqar Ahmed, Ahmed Faheem, Kevin M G Taylor.   

Abstract

The aerosol properties of niosomes were studied using Aeroneb Pro and Omron MicroAir vibrating-mesh nebulizers and Pari LC Sprint air-jet nebulizer. Proniosomes were prepared by coating sucrose particles with Span 60 (sorbitan monostearate), cholesterol and beclometasone dipropionate (BDP) (1:1:0.1). Nano-sized niosomes were produced by manual shaking of the proniosomes in deionized water followed by sonication (median size 236nm). The entrapment of BDP in proniosome-derived niosomes was higher than that in conventional thin film-made niosomes, being 36.4% and 27.5% respectively. All nebulizers generated aerosols with very high drug output, which was 83.6% using the Aeroneb Pro, 85.5% using the Pari and 72.4% using the Omron. The median droplet size was 3.32μm, 3.06μm and 4.86μm for the Aeroneb Pro, Pari and Omron nebulizers respectively and the "fine particle fraction" (FPF) of BDP was respectively 68.7%, 76.2% and 42.1%. The predicted extrathoracic deposition, based on size distribution of nebulized droplets was negligible for all devices, suggesting all of them are potentially suitable for pulmonary delivery of niosomes. The predicted drug deposition in the alveolar region was low using the Omron (3.2%), but greater using the Aeroneb Pro (17.4%) and the Pari (20.5%). Overall, noisome-BDP aerosols with high drug output and FPF can be generated from proniosomes and delivered using vibrating-mesh or air-jet nebulizers.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299083     DOI: 10.1016/j.ijpharm.2012.12.040

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Proniosome: A Promising Approach for Vesicular Drug Delivery.

Authors:  Marzina Ajrin; Fahmida Anjum
Journal:  Turk J Pharm Sci       Date:  2022-08-31

2.  In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration.

Authors:  H O Ammar; M Haider; M Ibrahim; N M El Hoffy
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Niosomal Nanocarriers for Enhanced Dermal Delivery of Epigallocatechin Gallate for Protection against Oxidative Stress of the Skin.

Authors:  Danhui Li; Nataly Martini; Zimei Wu; Shuo Chen; James Robert Falconer; Michelle Locke; Zhiwen Zhang; Jingyuan Wen
Journal:  Pharmaceutics       Date:  2022-03-28       Impact factor: 6.525

4.  In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin.

Authors:  Gyati Shilakari Asthana; Parveen Kumar Sharma; Abhay Asthana
Journal:  Scientifica (Cairo)       Date:  2016-05-16

5.  A Facile and Novel Approach to Manufacture Paclitaxel-Loaded Proliposome Tablet Formulations of Micro or Nano Vesicles for Nebulization.

Authors:  Iftikhar Khan; Katie Lau; Ruba Bnyan; Chahinez Houacine; Matthew Roberts; Abdullah Isreb; Abdelbary Elhissi; Sakib Yousaf
Journal:  Pharm Res       Date:  2020-06-02       Impact factor: 4.200

Review 6.  Proniosomes derived niosomes: recent advancements in drug delivery and targeting.

Authors:  Maryam Khatoon; Kifayat Ullah Shah; Fakhar Ud Din; Shefaat Ullah Shah; Asim Ur Rehman; Naz Dilawar; Ahmad Nawaz Khan
Journal:  Drug Deliv       Date:  2017       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.